Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Information source: University of Virginia
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Melanoma
Intervention: MELITAC 12.1 (Biological); Imiquimod (Drug)
Sponsored by: University of Virginia
Official(s) and/or principal investigator(s):
Craig L Slingluff, M.D., Principal Investigator, Affiliation: University of Virginia
The purpose of the study is to determine 1) the safety of administration of topical 5%
imiquimod cream with or without administration of a peptide-based vaccine in patients with
cutaneous metastases of melanoma and 2) evaluate whether topical imiquimod at sites of
melanoma metastasis, with or without vaccine, increases a) endothelial expression of
E-selectin and b) T cell infiltration.
Official title: Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Safety: To determine the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma.
Secondary outcome: Biologic: To evaluate whether topical imiquimod at sites of melanoma metastasis, with or without vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.
1) To determine the safety of administration of topical 5% imiquimod cream with or without
administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma.
1) To evaluate whether topical imiquimod at sites of melanoma metastasis, with or without
vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.
1. To assess whether T cells infiltrating melanoma metastases after imiquimod, with and
without vaccination, are reactive to peptides in the vaccine.
2. To evaluate whether topical imiquimod decreases the proportion of FoxP3+ CD25hi CD4+
cells (putative regulatory T cells, Tregs) among tumor infiltrating T cells.
3. To estimate the effects of vaccine on CXCR3, CLA, and activation marker expression by
circulating and tumor-infiltrating antigen-experienced CD4 and CD8 T cells.
4. To obtain preliminary data on the clinical response of cutaneous metastases of melanoma
to the proposed combination regimen.
5. To determine the expression of TLR7 by immune cells and/or melanoma cells in the
metastatic melanoma microenvironment.
6. To obtain preliminary data on associations between metastatic melanoma T cell
infiltration patterns (immunotypes) and molecular and clinical responses to imiquimod.
The present proposal is for a clinical trial and associated correlative studies that bring
together several observations and unmet scientific and clinical needs that have promise for
a new effective immunotherapy for melanoma metastases. This is an open-label two-cohort,
nonrandomized, pilot study of a combination of topical imiquimod plus systemic vaccination
with MELITAC 12. 1 vaccine, an emulsion of a mixture of 12 class I MHC-restricted melanoma
peptides (12-MP) and a class II MHC-restricted tetanus toxoid helper peptide (tet). Cohort
1 will receive the combination of imiquimod + vaccine; Cohort 2 will receive imiquimod only.
Patients will be eligible for cohort 1 if they are eligible for the vaccine based on HLA
type and clinical factors. Cohort 2 is for patients who are not eligible for the vaccine.
1) Toxicity profile of topical imiquimod at sites of melanoma, with or without MELITAC 12. 1
1) Change in levels of intratumoral E-selectin and infiltrating TCD4 and TCD8 lymphocytes:
1. pretreatment vs after vaccine + imiquimod;
2. with vaccine vs. without vaccine (cohorts 1 vs 2);
3. lesions with imiquimod vs. without imiquimod.
The following will be evaluated by comparing pretreatment to after vaccine + imiquimod, and
comparing findings from patients with and without vaccine (cohorts 1 and 2), as well as
lesions with and without imiquimod.
1. Change in the number of vaccine-reactive T cells in the melanoma metastases, as
determined by ELIspot and tetramer analyses.
2. Change in the percentage of FoxP3+ CD25hi CD4+ (putative regulatory T cells, Tregs)
among tumor infiltrating T cells as determined by immunohistochemistry and flow
3. Expression of CXCR3, CLA, and activation markers (CD69, CD137, HLA-DR, CD27 and CD28)
on vaccine-reactive cells in the blood and within the melanoma metastases by
immunohistochemistry and flow cytometric analyses.
4. TLR7 expression by cells in the metastatic melanoma microenvironment.
5. Changes in T cell infiltration patterns of metastases (immunotype)
The following will be evaluated post-treatment
6. Clinical regression of individual imiquimod-treated and untreated metastases
Minimum age: 18 Years.
Maximum age: N/A.
1. Participants with stage IIIB, IIIC or IV melanoma with cutaneous metastases.
2. Patients must have adequate cutaneous metastases of melanoma readily accessible for
biopsy to provide a minimum of 0. 3 cm3 of tissue per biopsy (approximately 0. 85 cm by
0. 85 cm x 0. 85 cm or five 2mm core biopsies) at each of three time points. Several
scenarios may fulfill the tumor burden requirement. For example, a patient may have
one large lesion from which core biopsies can be taken for the first and second
biopsy time points and then the entire lesion excised for the final tissue sample.
Other combinations are acceptable.
3. The intent is to limit this study to patients with cutaneous melanoma metastasis
rather than subcutaneous or lymph node metastasis because imiquimod may not penetrate
to those deeper metastases.
4. Patients may have had multiple primary melanomas.
5. Patients may have had or may have a metastasis from a cutaneous primary site, mucosal
primary site, ocular primary site, or unknown primary site.
6. Patients who have had brain metastases may be eligible if they meet the following
- Patients with less than or equal to 5 metastases may be eligible as long as the
following 3 criteria are true:
- The brain metastases have been completely removed by surgery or have been
treated completely by stereotactic radiotherapy. Stereotactic radiotherapy,
such as gamma knife, can be used up to 1 week prior to study entry.
- There has been no evident growth of any brain metastasis since treatment.
- No metastasis greater than 2 cm at the time of protocol entry
- Patients with greater than 5 metastases may be eligible if the above 3 criteria
are met and if at least one year has elapsed since the last treatment.
7. All participants must have ECOG performance status of 0 or 1 and ability and
willingness to give informed consent
8. Patients must have at least one intact axillary and/or inguinal lymph node basin. A
patient with a prior lymph node biopsy may be a candidate if lymphoscintigraphy
demonstrates intact drainage to a node in that basin. A lymphoscintigram may be
performed during screening to ensure that there is drainage to a regional node from a
planned vaccine site. If the lymphoscintigram is performed and a sentinel lymph node
is not located, the patient will be ineligible for this study if no other vaccine
sites are available.
9. Laboratory parameters as follows: The following laboratory parameters will be
required for all participants. If a lab value appears to be an error or a result of
a transient or treatable condition, the investigator will use his/her clinical
judgment to decide if the test may be repeated. The requirements for inclusion are
- HLA-A1, -A2, -A3, or -A11+
- ANC > 1000/mm3
- Platelets > 100,000/mm3
- Hgb ≥ 9 g/dL
- HGBA1C < 7%
- AST and ALT ≤ 2. 5 x upper limits of normal (ULN)
- Bilirubin ≤ 2. 5 x ULN
- Alkaline phosphatase ≤ 2. 5 x ULN
- Creatinine ≤ 1. 5 x ULN
- HIV negative (within 6 months of study entry)
- Hepatitis C negative (within 6 months of study entry)
- LDH up to 2 x ULN
10. Patients must be 18 years or older at study entry
1. Patients who have had brain metastases unless they meet the criteria outlined above
2. Patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or
other experimental therapy, or who have received this therapy within the preceding 4
weeks. Gamma knife or stereotactic radiosurgery may be administered within the prior
4 weeks, but must not be administered less than one week prior to study enrollment.
Patients who are currently receiving nitrosoureas or who have received this therapy
within the preceding 6 weeks.
3. Patients will not be eligible if there is clinically detectable melanoma deemed
likely by the investigator to require intervention during the first 12 weeks of the
study that would require premature discontinuation. Examples for such circumstances
may include untreated bone metastases at risk for fracture, and rapidly progressive
low volume disease.
4. Patients with known or suspected allergies to any component of the vaccine.
5. Patients receiving the following medications at study entry or within the preceding 4
weeks are excluded:
- Agents with putative immunomodulating activity (with the exception of
non-steroidal anti-inflammatory agents and topical steroids
- Allergy desensitization injections.
- Systemic corticosteroids, administered parenterally or orally. Inhaled steroids
(e. g. Advair®, Flovent®, Azmacort®) are not permitted. Topical corticosteroids
are acceptable, including steroids with very low solubility administered nasally
for local effects only (e. g. Nasonex®).
- Any pharmacologic growth factors (e. g. GM-CSF, G-CSF, erythropoietin).
- Interferon therapy.
- Interleukin-2 or other interleukins.
- Topical 5% Imiquimod cream: Patients must not have had imiquimod therapy to any
body site within 4 weeks of study entry and must not have had any prior
imiquimod therapy to the lesions to be treated, watched or biopsied on this
present study. If imiquimod has been used in the past and either led to
complete regression of the treated lesions, or those lesions have been removed
surgically, then the patient may be eligible.
6. Prior melanoma vaccinations may be an exclusion criterion in som circumstances:
- Patients who have recurred or progressed either after or during administration
of a melanoma vaccine may be eligible to enroll 12 weeks following their last
- Patients may have been vaccinated previously with peptide vaccines (including
MELITAC 12. 1 and similar vaccines) or with non-peptide vaccines.
7. Pregnancy or the possibility of becoming pregnant during vaccine administration.
Female patients of child-bearing potential must have a negative pregnancy test
(urinary or serum beta-HCG) prior to administration of the first vaccine dose. Males
and females must agree, in the consent form, to use effective birth control methods
during the course of vaccination. Women must also not be breast feeding. This is
consistent with existing standards of practice for vaccine and chemotherapy
8. Patients in whom there is a medical contraindication or potential problem in
complying with the requirements of the protocol, in the opinion of the investigator.
9. Patients classified according to the New York Heart Association classification as
having Class III or IV heart disease (Appendix 4).
10. Patients with a body weight < 110 lbs because of the amount and frequency with which
blood will be drawn
11. Participants must not have had prior autoimmune disorders requiring cytotoxic or
immunosuppressive therapy, or autoimmune disorders with visceral involvement.
Participants with an active autoimmune disorder requiring these therapies are also
excluded. The following will not be exclusionary:
- The presence of laboratory evidence of autoimmune disease (e. g. positive ANA
titer) without associated symptoms
- Clinical evidence of vitiligo
- Other forms of depigmenting illness
- Mild arthritis requiring NSAID medications or no medical therapy
Locations and Contacts
University of Virginia, Charlottesville, Virginia 22908, United States
Starting date: January 2011
Last updated: September 19, 2013